New Horizons in the Treatment of Metastatic Head and Neck Squamous
Cell Carcinoma (HNSCC): How Immunotherapies Are Changing the
Treatment Paradigm
 

New Horizons in the Treatment and Management of Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC): How Immunotherapies Are Changing the Treatment Paradigm is a 4-part webcast series that will provide attendees with the latest information in HNSCC Management.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 4 or in order.

These are archives of live webinars held on August 23, August 30, September 13 and September 20, 2017. If you participated in any of the live webinars, you are not eligible to claim credit from the archive of that webinar.

Each session is valid from November 1, 2017 to November 30, 2018

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate. To print or save your certificate, you will need to click on the “download” button and either print or save.

This series is supported by educational grants from Bayer Healthcare and Merck Sharp & Dohme Corp

 Description:  Head and neck squamous cell carcinoma (HNSCC) represents a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 48,330 new cases are diagnosed annually in the United States, and 9,570 people die of the disease. HNSCC historically has been associated with tobacco and alcohol use; however, during the past decade, infection with high-risk human papillomavirus (HPV) has been implicated in the pathogenesis of a growing subset of HNSCCs. Despite advances and innovations in multimodality treatment and a better understanding of head and neck carcinogenesis, survival rates of locally metastatic HNSCC have not substantially improved, and the prognosis for recurrent/metastatic disease remains poor. Fortunately for patients with metastatic HNSCC, new immunotherapeutic options, which have shown improved efficacy and safety, have recently become available to give clinicians and managed care professionals more options when managing a population of metastatic HNSCC patients. 

This webinar series on metastatic head and neck squamous cell carcinoma will educate attendees about recently updated clinical practice guidelines of metastatic HNSCC, the latest data on immunotherapies, strategies for integrating these options into the treatment paradigm, options for disease progression, strategies for managing adverse events and what managed care needs to know about immunotherapies in metastatic HNSCC.
 



 

Integrating Immunotherapies into the Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Treatment Paradigm
1.     Discuss the role of immunotherapies in the treatment of metastatic head and neck squamous cell carcinoma (HNSCC)
2.     Review recent clinical data on the use of immunotherapy in the management of metastatic HNSCC
3.     Individualize treatment with immunotherapeutic agents based on patient factors including tumor characteristics, treatment history, common adverse effects, and age for optimal care
4.     Assess key sequencing considerations when formulating a plan for individualized treatment in metastatic
5.     Discuss the potential impact of human papillomavirus (HPV), programmed cell death ligand 1 (PD-L1) status, and expression profiling on a patient's clinical response to immune checkpoint inhibitors

Physician, Nursing and CMCN credits valid to November 30, 2018

 

Managing Disease Progression in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC): What are the Options when Chemotherapy Fails?
1.     Discuss challenges associated with disease progression in metastatic HNSCC and strategies for managing therapy beyond the first line
2.     Analyze the relative benefits and limitations of immunotherapies for metastatic HNSCC following chemotherapy
3.     Assess strategies for optimal treatment switching for metastatic HNSCC patients whose disease progresses after platinum chemotherapy

Physician, Nursing and CMCN credits valid to November 30, 2018
 

Overcoming Barriers to Treatment in Metastatic HNSCC: Strategies to Manage Adverse Events Associated with Immunotherapies

1.     Discuss challenges and barriers that healthcare professionals face when managing metastatic HNSCC

2.     Identify adverse events commonly associated with immunotherapeutic agents used in the treatment of metastatic HNSCC

3.     Discuss strategies to mitigate side effects related to treatment with immunotherapeutic agents in patients with metastatic HNSCC

4.     Assess the informational needs of patients and families/caregivers regarding their treatment plan and identify methods to counsel them

5.     Review how treatment strategies can be affected by adverse events based on patient’s individualized needs

Physician, Nursing and CMCN credits valid to November 30, 2018
 

What Managed Care Needs to Know in the Evolving Management of Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

1.     Discuss methods to enable optimal cost management of evolving therapies, including immunotherapies, in the management of metastatic HNSCC to be realized by multiple oncology stakeholders including managed care organizations

2.     Analyze strategies used by managed care organizations to facilitate high quality care for members with HNSCC, and how newer therapies affect those strategies

3.     Assess important points that payers need to know about the use of immunotherapies in metastatic HNSCC

Physician, Nursing and CMCN credits valid to November 30, 2018